Utilization of Filgrastim and Infliximab Biosimilar Products in Medicare Part D, 2015-2019.
cross_sectional · Level IV
Where this comes from
- Record sourced from PubMed, PMID 35254434.
- Also identified by DOI 10.1001/jamanetworkopen.2022.1117 and PMC identifier 8902649.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
This cross-sectional study examines utilization trends for filgrastim and infliximab products and their biosimilars to understand whether biosimilars are associated with reduced spending in Medicare Part D.
Medical subject headings
- Biosimilar Pharmaceuticals
- Medicare Part D